Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma - Summary - MDSpire

Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

  • By

  • Christen M. Dillard

  • Hans Lee

  • Nilesh Kalariya

  • Naveen Subramanian

  • Oren Pasvolsky

  • Christopher Ferreri

  • Mahmoud Gaballa

  • Sheeba K. Thomas

  • Donna M. Weber

  • Melody Becnel

  • Gregory Kaufman

  • Muzaffar Qazilbash

  • Robert Z. Orlowski

  • Michelle A. T. Hildebrandt

  • Krina K. Patel

  • April 13, 2026

  • 0 min

Share

Objective:

To investigate the associations between genetic ancestry and CAR-T outcomes in patients with relapsed/refractory multiple myeloma (RRMM), highlighting the significance of these outcomes.

Key Findings:
  • No significant differences in overall response rate (ORR), progression-free survival (PFS), or overall survival (OS) by genetic ancestry, suggesting the need for tailored treatment strategies.
  • Patients with higher African ancestry (AFR) exhibited more aggressive disease features, indicating a potential need for more intensive treatment.
  • Patients with higher European ancestry (EUR) had fewer prior lines of therapy and lower rates of organ involvement, which may influence treatment decisions.
Interpretation:

Genetic ancestry may provide a more precise understanding of biologically relevant factors influencing CAR-T therapy outcomes, despite no significant differences in efficacy or safety observed; further research is essential to explore these associations.

Limitations:
  • Single-center study may limit generalizability and introduce bias.
  • Retrospective design may introduce bias, and potential confounding factors should be considered.
  • Small sample size for certain ancestry groups limits the robustness of findings.
Conclusion:

Genetic ancestry is a relevant factor in understanding treatment outcomes in RRMM, but further research is needed to clarify its impact on CAR-T therapy, particularly in diverse populations.

Original Source(s)

Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

  • by Christen M. Dillard, Hans Lee, Nilesh Kalariya, Naveen Subramanian, Oren Pasvolsky, Christopher Ferreri, Mahmoud Gaballa, Sheeba K. Thomas, Donna M. Weber, Melody Becnel, Gregory Kaufman, Muzaffar Qazilbash, Robert Z. Orlowski, Michelle A. T. Hildebrandt, Krina K. Patel

  • April 13, 2026

Related Content

Case Study: Non-secretory Multiple Myeloma with Eosinophilia - Diagnostic Hurdles and a Comprehensive Literature Review

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma

Association of ciltacabtagene autoleucel with immune effector cell-associated enterocolitis: insights from a large national database